Loyzide 40mg Tablet contains Gliclazide, a sulfonylurea class oral hypoglycemic agent used in the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby lowering blood glucose levels. Loyzide is indicated for patients with type 2 diabetes who have inadequate glycemic control through diet and exercise alone. The 40mg dosage allows for flexible titration based on individual patient response and glycemic targets. Gliclazide is characterized by a relatively low risk of hypoglycemia compared to other sulfonylureas and may also exhibit antioxidant properties that could confer vascular benefits. It is typically administered once daily with breakfast to optimize efficacy and minimize adverse effects. Common side effects include hypoglycemia, gastrointestinal disturbances, and allergic skin reactions. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Regular monitoring of blood glucose and HbA1c levels is essential to assess therapeutic response and adjust dosage accordingly. Patient education on recognizing hypoglycemia symptoms and adherence to lifestyle modifications is critical for optimal diabetes management with Loyzide 40mg Tablet.